Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Mol Cell Neurosci. 2017 Apr 9;82:105–117. doi: 10.1016/j.mcn.2017.04.001

Figure 5.

Figure 5

Chronic treatment with paclitaxel does not attenuate the basal phosphorylation level or membrane localization of PKC α, βI or βII in cultured sensory neurons. (A, C, E) Representative western blot images showing immunoreactivity for PKC α, βI and βII in cytosolic and membrane fractions of neurons treated with vehicle and paclitaxel (300 nM, 3 days). (B, D, F) Densitometry analysis showing no significant differences in PKC immunoreactivity in paclitaxel-treated (300 nM, 3 days) neurons compared to vehicle-treated neurons in cytosolic and membrane fractions when normalized to actin and Na+/K+ ATPase α, respectively. Significance was determined using a two-way ANOVA with Tukey’s post-hoc test (N = 3–4, a.u. ± SEM). Veh - Vehicle; Pac -Paclitaxel.